Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of ravulizumab in adults with generalized myasthenia gravis naive to complement inhibitors
MOH_2019-04-16_006090Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in myasthenia gravis (MG) (3 arms), sponsored by Alexion Pharmaceuticals. Started Apr 2019; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2019-04-16_006090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-16_006090.